Merck Positions MK-8591 As Backbone For HIV Treatment And Prophylaxis
First-in-class antiviral could be a potential backbone for combo regimens and entry into PrEP. New data releases at IAS highlight potential in both settings.
First-in-class antiviral could be a potential backbone for combo regimens and entry into PrEP. New data releases at IAS highlight potential in both settings.